A new peer-reviewed clinical study investigating Bonolive® – Solabia Nutrition’s flagship olive leaf extract for women’s health – has been published in an international scientific journal. The study was conducted by Solabia Nutrition’s internal R&D team in collaboration with researchers at Maastricht University.

This randomized, double-blind, placebo-controlled trial examined whether 12 weeks of Bonolive® supplementation could influence circulating biomarkers of tissue aging and remodeling in menopausal women, while also exploring Bonolive®’s effects on skin quality in an exploratory subgroup.

Bonolive®: award-winning olive leaf extract for women’s health

Bonolive® is a clinically validated extract from Manzanilla olive leaves, standardized for 40% oleuropein. In previous published clinical studies in menopausal women, Bonolive® has established its beneficial effects on increasing bone-formation markers, reducing joint pain and improving blood lipid profile – all key domains for Menopausal women’s quality of life!

The Study:

Olive Leaf Extract Supplementation and Biomarkers of Systemic Aging: A Randomized, Double-Blind, Placebo-Controlled Trial in Postmenopausal Women

– full text available here.

Introduction

Olive leaf extract is rich in polyphenolic compounds such as oleuropein and hydroxytyrosol, which have demonstrated potent antioxidant and anti-inflammatory properties. These bioactive compounds are known to counteract key mechanisms of tissue aging, including oxidative stress and protein glycation. The skin is particularly sensitive to oxidative stress and extracellular matrix remodeling, processes highly relevant during menopausal aging. +31 43 711 4555 contact@solabia.com www.solabianutrition.com

Methods

A total of 65 healthy menopausal women (45–70 years) were randomized to consume either 250 mg Bonolive® or placebo daily for 12 weeks. Systemic markers evaluated included: elastin, collagen, hydroxyproline, pentosidine (an advanced glycation end product), and fasting glucose. In an exploratory subgroup of 26 participants, skin structure and quality were assessed using video dermoscopy at baseline, week 6, and week 12.

Results

Systemic Biomarkers

Bonolive® demonstrated notable effects on markers associated with tissue aging. The following trends were observed:

• Pentosidine is one of the advanced glycation end products and a key marker of cellular aging. It decreased in the Bonolive® group versus placebo.
• Elastin levels remained stable with Bonolive®, while they increased in the placebo group, indicating a protective effect of Bonolive® on tissue integrity.

Skin Microstructure (Dermoscopy Subgroup)

In the dermoscopy subgroup, Bonolive® supplementation was associated with measurable improvements in skin microstructure:

• A significant reduction in pore number between weeks 6 and 12 (p = 0.0012).
• At week 12, the Bonolive® group had significantly fewer pores compared to placebo (p = 0.034).
• Surface skewness, an indicator of skin texture, improved significantly with Bonolive® intake (p = 0.02).

These exploratory findings point toward a localized dermal effect of Bonolive® on skin microstructure.